Feb. 20, 2006 -- A widely prescribed asthma and allergy drug proved to be no more effective for treating hay fever symptoms than a much cheaper over-the-counter decongestant in a newly reported study.
Hay fever sufferers in the study who took the over-the-counter drug Sudafed 24 Hour (pseudoephedrine) also experienced no more sleep problems or other side effects than people who took the prescription drug Singulair.
That came as a big surprise to the researchers, who expected to see more restlessness and insomnia among the pseudoephedrine users.
"It may be that sleep problems weren't an issue because the people in the study took the once-a-day dose (240 milligrams) of pseudoephedrine in the morning," study co-author Robert M. Naclerio, MD, tells WebMD. "[Hay fever] symptoms also improved, and this was likely to have a positive effect on sleep."
40 Million Sufferers
More than 40 million Americans suffer from seasonal hay fever, known medically as allergic rhinitis.
In the head-to-head comparison, Sudafed 24 Hour and Singulair proved equally effective for treating the most common hay fever symptoms, such as sneezing, nasal congestion, runny nose, and nose and throat itchiness.
The University of Chicago study included 30 hay fever sufferers who took 10-milligram doses of montelukast (Singulair) each morning for two weeks and 28 who took the once-a-day, 240-milligram dosage of pseudoephedrine. The study was financed by Singulair manufacturer Merck & Co. Inc. Merck is a WebMD sponsor.
Time-released 240-milligram capsules of pseudoephedrine cost about 80 cents a day on line, compared with nearly $3 for 10 milligrams of Singulair.
"Our hypothesis was that montelukast would have additional benefits and pseudoephedrine would interfere with sleep, but when we compared them head-to-head we found that for the treatment of allergic rhinitis, these drugs were virtually identical," says researcher Fuad M. Baroody, MD.
The over-the-counter pseudoephedrine actually proved to be slightly more effective for reducing nasal congestion than Singulair, the researchers wrote.
The study is published in the February issue of the Archives of Otolaryngology - Head and Neck Surgery.
SOURCES: Mucha, S.M. Archives of Otolaryngology - Head
and Neck Surgery, February 2006; vol 132: pp 164-172. Robert M. Naclerio,
MD, professor of surgery; chief of otolaryngology, head, and neck surgery, The
Pritzker School of Medicine, University of Chicago. Fuad M. Baroody, MD,
University of Chicago. Philip E. Gallagher, MD, Allergy and Asthma Associates
of NW Pennsylvania, Erie, Pa; spokesman, American Academy of Allergy, Asthma,